Agenus Inc. Stock

$7.06

19.26%

Nasdaq, Jul 11, 10:14 pm CET

ISIN

US00847G7051

Symbol

AGEN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Agenus Inc. Stock price

$7.06

-62.42 89.84% 5Y

Nasdaq, Closing price Fri, Jul 11 2025

+1.14 19.26%

ISIN

US00847G7051

Symbol

AGEN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$193.6m

Enterprise Value

$210.6m

Net debt

$17.1m

Cash

$18.5m

Shares outstanding

26.6m

Valuation (TTM | estimate)

P/E

negative | 14.2

P/S

1.9 | 1.5

EV/Sales

2.1 | 1.6

EV/FCF

negative

P/B

negative

Financial Health

Equity Ratio

-144.2%

Return on Equity

69.7%

ROCE

1,245.7%

ROIC

Debt/Equity

-0.1

Financials (TTM | estimate)

Revenue

$99.5m | $129.7m

EBITDA

$-87.7m | $-148.1m

EBIT

$-100.9m | $11.5m

Net Income

$-190.8m | $13.2m

Free Cash Flow

$-146.3m

Growth (TTM | estimate)

Revenue

-38.4% | 25.3%

EBITDA

29.2% | -33.3%

EBIT

27.0% | 109.3%

Net Income

20.4% | 105.8%

Free Cash Flow

31.0%

EPS

$-7.8

FCF per Share

$-5.5

Short interest

11.9%

Employees

316

Rev per Employee

$330.0k

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

Agenus Inc. Stock Analysis

Unlock Scores for Free

??

11 Analysts have issued a Agenus Inc. forecast:

7x Buy

64%

4x Hold

36%

More details on Analyst Estimates Including Price Targets

11 Analysts have issued a Agenus Inc. forecast:

Buy

64%

Hold

36%

Analyst Estimates with Stock Price Targets

Financial data from Agenus Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	100 100	38% 38% 100%
- Direct Costs	0.52 0.52	43% 43% 1%
Gross Profit	99 99	38% 38% 99%
- Selling and Administrative Expenses	71 71	9% 9% 71%
- Research and Development Expense	133 133	40% 40% 134%
EBITDA	-88 -88	29% 29% -88%
- Depreciation and Amortization	13 13	9% 9% 13%
EBIT (Operating Income) EBIT	-101 -101	27% 27% -101%
Net Profit	-191 -191	20% 20% -192%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Agenus Inc. Stock News

Neutral

Business Wire

●

7 days ago

Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3

LEXINGTON, Mass.--(BUSINESS WIRE)-- #CancerCare--Agenus Inc. (Nasdaq: AGEN) a leader in immuno-oncology innovation, today announced that its botensilimab and balstilimab (BOT/BAL) combination achieved a two-year survival rate of 42% along with a now more mature 21-month median overall survival (OS) in an expanded cohort of 123 patients with microsatellite-stable (MSS) metastatic colorectal canc...

Neutral

Business Wire

●

27 days ago

Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology

LEXINGTON, Mass. & SAN FRANCISCO--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN) a leader in immuno-oncology innovation and Noetik, a leader in AI-driven spatial and multimodal biology, today announced a research collaboration to develop predictive biomarkers of response to Agenus' lead clinical stage immuno-oncology (IO) combination, botensilimab (BOT, multifunctional Fc-enhanced anti-CTLA-4) and...

Neutral

Business Wire

●

27 days ago

Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology

LEXINGTON, Mass. & SAN FRANCISCO--(BUSINESS WIRE)-- #aiinbiotech--Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology.

More Agenus Inc. News

Company Profile

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.

Head office	United States
CEO	Garo Armen
Employees	316
Founded	1994
Website	agenusbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now